Allergy Relief - Clinically Proven / Human Trials – Randomized, Double-blind, Placebo-controlled study
Allergy Relief Fast Acting
Clinically Proven / Human Trials – Randomized, Double-blind, Placebo-controlled study
A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study Annie-Claude Benichou Marion Armanet Anthony Bussière Nathalie Chevreau Jean-Michel Cardot Jan Tétard First published: 20 July 2014 https://doi.org/10.1002/fsn3.147
Abstract Occasional rhinitis symptoms caused by exposure to pollution or allergens is a growing concern. Based first on empirical observation of a lesser occurrence of allergies in quail farmers and then scientific works on ovomucoids properties, we developed a dietary supplement for the relief of such occasional rhinitis symptoms. The objective of the study was to determine whether one acute oral dose of the study product attenuates nasal provocation and other allergy-related symptoms after exposure to a standardized allergenic challenge as compared to placebo. Healthy subjects were recruited to participate in a randomized, double-blind, two-arm crossover, placebo-controlled, clinical trial. One acute dose of either the active study product (proprietary blend of quail egg) or placebo was given concomitantly to the standardized allergenic challenge. The primary endpoint was peak nasal inspiratory flow (PNIF) measurement and the secondary endpoints were subjects' perceived feelings of well-being based on Visual Analog Scale (VAS) scores for allergy-related symptoms, as well as immunoglobulin E count. Forty-three healthy subjects were enrolled and evaluable in a per protocol analysis. A gradual increase in PNIF from nadir up to Time 120 reflected the normal, gradual recovery from nasal obstruction induced by allergenic challenge for both the active and the placebo groups. At all post challenge time points, the active group had higher PNIF values compared to the placebo group, indicating that the active product was associated with fewer symptoms and reduced intensity of these symptoms. The active product resulted also in statistically significant improvements of most of the subjects' perceived feelings of well-being based on VAS scores. No adverse events occurred during the study. In conclusion, the dietary supplement consisting of proprietary blend made of quail eggs provides fast and efficient relief of allergic rhinitis symptoms caused by the most common outdoor and indoor allergens, without adverse events.
Figure 1 Average peak nasal inspiratory flow (PNIF) for active and placebo groups according to time in minutes for n = 43 (per protocol population). *Marginal significance at time 15 min, P = 0.0620 (post hoc analysis).
Figure 2 Percentage of improvement of average VAS results associated with active product versus placebo: (VASplacebo − VASactive)/VASplacebo. All data above the red line indicates that the differences between the active Figure 2 product and the placebo are significant.